Negative pressure wound therapy does not decrease postoperative wound complications in patients undergoing mastectomy and flap fixation.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
05 05 2021
Historique:
received: 20 01 2021
accepted: 19 04 2021
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 25 2 2023
Statut: epublish

Résumé

Patients and breast cancer surgeons are frequently confronted with wound complications after mastectomy. Negative pressure wound therapy (NPWT) is a promising technique for preventing wound complications after skin closure in elective surgery. However, a clinical study evaluating postoperative complications following the use of NPWT, focusing solely on closed incisions in patients undergoing mastectomy, has yet to be performed. Between June 2019 and February 2020, 50 consecutive patients underwent mastectomy with NPWT during the first seven postoperative days. This group was compared to a cohort of patients taking part in a randomized controlled trial between June 2014 and July 2018. Primary outcome was the rate of postoperative wound complications, i.e. surgical site infections, wound necrosis or wound dehiscence during the first three postoperative months. Secondary outcomes were the number of patients requiring unplanned visits to the hospital and developing clinically significant seroma (CSS). In total, 161 patients were analyzed, of whom 111 patients in the control group (CON) and 50 patients in the NPWT group (NPWT). Twenty-eight percent of the patients in the NPWT group developed postoperative wound complications, compared to 18.9% in the control group (OR = 1.67 (95% CI 0.77-3.63), p = 0.199). The number of patients requiring unplanned visits or developing CSS was not statistically significant between the groups. This study suggests that Avelle negative pressure wound therapy in mastectomy wounds does not lead to fewer postoperative wound complications. Additionally, it does not lead to fewer patients requiring unplanned visits or fewer patients developing clinically significant seromas.Trial registration: ClinicalTrials.gov number, NCT03942575. Date of registration: 08/05/2019.

Identifiants

pubmed: 33953312
doi: 10.1038/s41598-021-89036-3
pii: 10.1038/s41598-021-89036-3
pmc: PMC8100146
doi:

Banques de données

ClinicalTrials.gov
['NCT03942575']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9620

Références

J Wound Care. 2018 Mar 1;27(Sup3):S5-S13
pubmed: 29509094
Plast Reconstr Surg Glob Open. 2018 Jun 15;6(6):e1732
pubmed: 30276035
Cochrane Database Syst Rev. 2019 Mar 26;3:CD009261
pubmed: 30912582
JBI Database System Rev Implement Rep. 2015 Jan;13(1):253-303
pubmed: 26447018
BMC Cancer. 2018 Aug 17;18(1):830
pubmed: 30119663
Clin Breast Cancer. 2017 Jul;17(4):316-321
pubmed: 28202253
World J Surg. 2020 May;44(5):1526-1537
pubmed: 31900568
Ann Surg Oncol. 2021 May;28(5):2599-2608
pubmed: 33078318
Hand Clin. 2010 May;26(2):265-80
pubmed: 20494752
Ann Surg Oncol. 2014 Mar;21(3):802-7
pubmed: 24217790
Surg Infect (Larchmt). 2017 Oct;18(7):810-819
pubmed: 28885895
Aesthetic Plast Surg. 2018 Aug;42(4):927-935
pubmed: 29442143
Int Wound J. 2016 Dec;13(6):1260-1281
pubmed: 26424609
Br J Surg. 2016 Apr;103(5):477-86
pubmed: 26994715
Plast Reconstr Surg Glob Open. 2018 Aug 07;6(8):e1880
pubmed: 30324063
Contemp Oncol (Pozn). 2019;23(2):69-73
pubmed: 31316287
Surg Infect (Larchmt). 2014 Dec;15(6):679-85
pubmed: 24871230
Breast Cancer Res Treat. 2018 Jan;167(2):409-416
pubmed: 29039118
J Breast Health. 2016 Apr 01;12(2):91-93
pubmed: 28331742
Plast Reconstr Surg Glob Open. 2018 Jan 12;6(1):e1560
pubmed: 29464150
Plast Reconstr Surg. 2015 Sep;136(3):592-602
pubmed: 26313829

Auteurs

L De Rooij (L)

Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130 MB, Sittard, The Netherlands. l.derooij@zuyderland.nl.

S M J van Kuijk (SMJ)

Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.

E R M van Haaren (ERM)

Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130 MB, Sittard, The Netherlands.

A Janssen (A)

Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130 MB, Sittard, The Netherlands.

Y L J Vissers (YLJ)

Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130 MB, Sittard, The Netherlands.

G L Beets (GL)

Department of Surgery, Antoni Van Leeuwenhoek Hospital, Netherlands Cancer Institute, Amsterdam, The Netherlands.
GROW School for Oncology and Developmental Biology, University of Maastricht, Maastricht, The Netherlands.

J van Bastelaar (J)

Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130 MB, Sittard, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH